Intellia Therapeutics, Inc. NTLA
We take great care to ensure that the data presented and summarized in this overview for Intellia Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NTLA
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$111 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$90.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$85.1 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$46.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$33.8 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.99MShares$26.5 Million0.39% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.83MShares$25.1 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.49MShares$22.1 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.39MShares$21.2 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.31MShares$20.5 Million0.04% of portfolio
Latest Institutional Activity in NTLA
Top Purchases
Top Sells
About NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NTLA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 29
2025
|
Muna Bhanji |
SELL
Open market or private sale
|
Direct |
265
-1.36%
|
$2,120
$8.5 P/Share
|
|
Mar 04
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
679
-0.71%
|
$5,432
$8.99 P/Share
|
|
Mar 04
2025
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,572
-2.25%
|
$20,576
$8.99 P/Share
|
|
Mar 01
2025
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
136,000
+11.21%
|
-
|
|
Mar 01
2025
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+24.99%
|
-
|
|
Mar 01
2025
|
Edward J Dulac Iii EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,200
+29.37%
|
-
|
|
Mar 01
2025
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,200
+24.82%
|
-
|
|
Mar 01
2025
|
Michael P Dube VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+19.01%
|
-
|
|
Mar 01
2025
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+25.89%
|
-
|
|
Mar 01
2025
|
Birgit C Schultes EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,600
+26.33%
|
-
|
|
Jan 29
2025
|
Muna Bhanji |
SELL
Open market or private sale
|
Direct |
265
-1.34%
|
$2,385
$9.97 P/Share
|
|
Jan 03
2025
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
26,807
-2.77%
|
$321,684
$12.18 P/Share
|
|
Jan 03
2025
|
Derek Hicks EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,502
-9.8%
|
$78,024
$12.18 P/Share
|
|
Jan 03
2025
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,557
-9.83%
|
$114,684
$12.18 P/Share
|
|
Jan 03
2025
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
7,074
-8.67%
|
$84,888
$12.18 P/Share
|
|
Jan 03
2025
|
Michael P Dube VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,372
-2.92%
|
$16,464
$12.18 P/Share
|
|
Jan 03
2025
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,966
-10.38%
|
$107,592
$12.18 P/Share
|
|
Jan 03
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
7,422
-10.38%
|
$89,064
$12.18 P/Share
|
|
Jan 02
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
556
-0.77%
|
$6,672
$12.03 P/Share
|
|
Jan 01
2025
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,850
+0.8%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 496K shares |
|---|---|
| Exercise of conversion of derivative security | 14.5K shares |
| Open market or private sale | 76K shares |
|---|